New Launch15 Sept 2025, 07:03 pm
Zydus Lifesciences Launches First Generic Treatment for Canine Urinary Incontinence and Affordable Furosemide Tablets for Long-term Heart Care
AI Summary
Zydus Lifesciences Ltd, through its subsidiary ZyVet® Animal Health, has launched two significant products. The first is a generic treatment for canine urinary incontinence using phenylpropanolamine hydrochloride tablets. The second is an affordable version of Furosemide tablets, a critical therapy for managing congestive heart failure and chronic fluid retention in dogs and cats. These launches reinforce ZyVet's commitment to bringing trusted, high-quality, and cost-effective therapies to veterinary professionals across the United States.
Key Highlights
- ZyVet® has launched the first FDA-approved generic of phenylpropanolamine hydrochloride tablets, a trusted treatment for managing urinary incontinence in dogs.
- The phenylpropanolamine hydrochloride tablets are designed with the needs of both veterinary teams and pet owners in mind, available in multiple strengths to support precise dosing.
- ZyVet® has also announced the launch of the first veterinary approved generic of Furosemide Tablets, a critical therapy for managing congestive heart failure and chronic fluid retention in dogs and cats.
- These launches reinforce ZyVet's commitment to bringing trusted, high-quality, and cost-effective therapies to veterinary professionals across the United States.
- ZyVet®, a division of Zydus Lifesciences, benefits from more than 70 years of pharmaceutical, R&D, Regulatory, QA/QC, manufacturing scale, excellence and expertise.